Polycystic ovary syndrome: 3 key challenges
OBG Management. 2003 June;15(06):62-72
June 1, 2003 | OBG Management
Author and Disclosure Information
Newer findings have broadened options for medical management of insulin resistance, anovulation, and hyperandrogenism.
TABLE 2
Medical therapies for PCOS-associated hirsutism
| AGENT | DOSE | MAJOR SIDE EFFECTS | FDA-APPROVED USE | |
|---|---|---|---|---|
| Androgen-receptor antagonists | ||||
| Flutamide | 250 mg/d | Elevated liver enzymes | Adjuvant for prostate cancer | |
| Dry skin | ||||
| Urine discoloration | ||||
| Spironolactone | 25-100 mg/d | Polyuria | Diuretic | |
| Orthostatic hypotension | ||||
| Hyperkalemia | ||||
| Cyproterone acetate | 100 mg/d | Adrenal insufficiency | Not available in United States | |
| Loss of libido | ||||
| 5α-reductase inhibitor | ||||
| Finasteride | 1-5 mg/d | Teratogenic in a male fetus | Male alopecia | |
| Prostate cancer | ||||
Dr. Stovall reports no affiliations or financial arrangements with any of the manufacturers of products mentioned in this article.
